Irbetan tablets 300 mg. №20

Description

Irbetan Composition
active substance: 1 tablet contains 300 mg of irbesartan;

excipients: lactose monohydrate, microcrystalline cellulose, pregelatinized starch, croscarmellose sodium, poloxamer, colloidal silicon dioxide

anhydrous, magnesium stearate.

Irbetan Dosage form
Pills.

Basic physical and chemical properties: round tablets with a biconvex surface, white or almost white, with a line.

Irbetan Pharmacotherapeutic group
Angiotensin II receptor antagonists, simple drugs. ATX code С09С А04.

Pharmacodynamics
Mechanism of action. Irbesartan is a potent, orally active, selective angiotensin II receptor antagonist (type AT1). It can block all the effects of angiotensin II mediated by the AT1 receptor, regardless of the source or route of synthesis of angiotensin II.

Selective antagonism of angiotensin II (AT1) receptors causes an increase in the level of renin and angiotensin II in the blood plasma, as well as a decrease in the concentration of aldosterone in the blood plasma. At the level of potassium in the blood serum, irbesartan by itself, if used in the recommended doses, does not have a significant effect. Irbesartan does not inhibit the angiotensin-converting enzyme (kininase II), an enzyme that catalyzes the formation of angiotensin II and the degradation of bradykinin to inactive metabolites. Irbesartan is active without metabolic activation.

Clinical efficacy

Arterial hypertension. Irbesartan lowers blood pressure by minimally altering the heart rate. The decrease in blood pressure is dose-dependent, with a tendency to plateau levels with doses greater than 300 mg. When using the drug in doses of 150-300 mg 1 time per day, blood pressure in the supine or sitting position at the time of the minimum efficacy of the drug (that is, 24 hours after taking the dose) is on average 8-13 / 5-8 mm Hg … (systolic / diastolic) is lower than with placebo.

Indications

Treatment of essential arterial hypertension in adults.
Treatment of chronic kidney disease in adult patients with arterial hypertension and type II diabetes mellitus as part of the antihypertensive therapy regimen.

Contraindications

Hypersensitivity to the active substance or to any of the excipients (see section “Composition”).
Pregnant women or women planning pregnancy (see section “Use during pregnancy or lactation”).
The simultaneous use of the drug Irbetan with drugs containing aliskiren is contraindicated in patients with diabetes mellitus or renal dysfunction (glomerular filtration rate (GFR) <60 ml / min / 1.73 m2) (see the section “Interaction with other drugs and other types of interactions “).